KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accounts Payables: 2017-2024

Historic Accounts Payables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $735.5 million.

  • Amneal Pharmaceuticals' Accounts Payables rose 9.05% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year increase of 9.05%. This contributed to the annual value of $735.5 million for FY2024, which is 37.55% up from last year.
  • Amneal Pharmaceuticals' Accounts Payables amounted to $735.5 million in FY2024, which was up 37.55% from $534.7 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Accounts Payables registered a high of $735.5 million during FY2024, and its lowest value of $525.3 million during FY2021.
  • Over the past 3 years, Amneal Pharmaceuticals' median Accounts Payables value was $538.2 million (recorded in 2022), while the average stood at $602.8 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Accounts Payables fell by 14.14% in 2021, and later surged by 37.55% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Accounts Payables stood at $611.9 million in 2020, then fell by 14.14% to $525.3 million in 2021, then rose by 2.45% to $538.2 million in 2022, then dropped by 0.66% to $534.7 million in 2023, then surged by 37.55% to $735.5 million in 2024.